Thyroxine in acute myocardial infarctio

Phase 4

Completed

• Conditions: Subtopic: Metabolic and Endocrine (all Subtopics); Topic: Metabolic and endocrine disorders; Disease: Metabolic & Endocrine (not diabetes); Nutritional, Metabolic, Endocrine

• Registration Number: ISRCTN52505169
• Lead Sponsor: Gateshead Health NHS Foundation Trust

Brief Summary

1. 2015 protocol in http://www.ncbi.nlm.nih.gov/pubmed/25872532 2. 2017 results presented at Society for Endocrinology BES 2017: DOI: 10.1530/endoabs.50.P386 3. 2020 results in https://pubmed.ncbi.nlm.nih.gov/32692386/ (added 22/07/2020)

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2015-01-09
• Study Completion: 2018-04-30
• Last Update Posted: 3 August 2020

Recruitment & Eligibility

• Status: Completed
• Sex: All
• Target Recruitment: 95

Inclusion Criteria

1. Males and females aged between 18-75 yrs
2. Serum TSH between 4.01 -10.00 mU/L with normal free thyroxine levels (9 – 25 pmol/L) on two occasions (on day of admission for AMI and 7-10 days after AMI)
3. Acute myocardial infarction diagnosed on admission to hospital (chest pain with dynamic ECG changes or increase troponin enzymes (at least a fourfold increase above normal range)

Exclusion Criteria

1. Patients on medications affecting thyroid function (levothyroxine, carbimazole, propylthiouracil, amiodarone, lithium)
2. Patients who are unable to provide written informed consent
3. Patients with advanced malignancy (who, in the opinion of the investigator, is unlikely to survive for more than 6 months)
4. Patients with sustained ventricular tachycardia requiring treatment which occurs >24hrs after myocardial re-perfusion/revascularisation
5. Patients who have contra-indications to MR scanning (cardiac pacemaker, metallic heart valves, cochlear implants, coronary artery stents incompatible with MR scanning, etc.)
6. Patients who are unlikely or unwilling, in the opinion of the investigator, to attend for study specific visits
7. Participants whose serum TSH is >10.0 or <4.0 on either occasion
8. Patients who are already participating in another interventional study

Study & Design

• Study Type: Interventional
• Study Design: Not specified